# Terazosin and Parkinson's Disease Extension Study

> **NCT05109364** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Cedars-Sinai Medical Center** · enrollment: 15 (estimated)

## Conditions studied

- Symptomatic Parkinson Disease
- REM Sleep Behavior Disorder
- Pre-motor Parkinson's Disease

## Interventions

- **DRUG:** Terazosin therapy

## Key facts

- **NCT ID:** NCT05109364
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-23
- **Primary completion:** 2026-03-10
- **Final completion:** 2026-03-10
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05109364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05109364, "Terazosin and Parkinson's Disease Extension Study". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05109364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*